AAAAAA

   
Results: 1-7 |
Results: 7
EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 7 YEARSOF ACTIVE EUROPEAN COLLABORATION
Authors: AWADA A CUFER T BEEX L COLEMAN R PARIDAENS R BRUNING P KLIJN J NOOIJ M MAURIAC L VANVRECKEM A BIGANZOLI L PICCART MJ
Citation: A. Awada et al., EORTC-IDBBC (INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER) - 7 YEARSOF ACTIVE EUROPEAN COLLABORATION, European journal of cancer, 34, 1998, pp. 86-86
VOROZOLE (R83842) IN THE TREATMENT OF POSTMENOPAUSAL ADVANCED BREAST-CANCER - RELATIONSHIP OF SERUM LEVELS OF VOROZOLE AND CLINICAL-RESULTS(A STUDY OF THE EORTC BREAST-CANCER COOPERATIVE GROUP)
Authors: BRUNING PF BONFRER JMG PARIDAENS R NOOIJ M KLIJN JGM BEEX LVAM BRUYNSEELS J PICCART MJ
Citation: Pf. Bruning et al., VOROZOLE (R83842) IN THE TREATMENT OF POSTMENOPAUSAL ADVANCED BREAST-CANCER - RELATIONSHIP OF SERUM LEVELS OF VOROZOLE AND CLINICAL-RESULTS(A STUDY OF THE EORTC BREAST-CANCER COOPERATIVE GROUP), Anti-cancer drugs, 9(5), 1998, pp. 419-425
VOROZOLE (RIVIZOR(TM)) - AN ACTIVE AND WELL TOLERATED NEW AROMATASE INHIBITOR FOR THE TREATMENT OF ADVANCED BREAST-CANCER PATIENTS WITH PRIOR TAMOXIFEN EXPOSURE
Authors: PARIDAENS R ROY JA NOOIJ M KLIJN J HOUSTON SJ BEEX LVAM VINHOLES J TOMIAK E VANVRECKEM A LANGENAEKEN C VANGLABBEKE M PICCART MJ
Citation: R. Paridaens et al., VOROZOLE (RIVIZOR(TM)) - AN ACTIVE AND WELL TOLERATED NEW AROMATASE INHIBITOR FOR THE TREATMENT OF ADVANCED BREAST-CANCER PATIENTS WITH PRIOR TAMOXIFEN EXPOSURE, Anti-cancer drugs, 9(1), 1998, pp. 29-35
CORTICOSTEROIDS SIGNIFICANTLY DELAY THE ONSET OF DOCETAXEL-INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED STUDY OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER
Authors: PICCART MJ KLIJN J PARIDAENS R NOOIJ M MAURIAC L COLEMAN R BONTENBAL M AWADA A SELLESLAGS J VANVRECKEM A VANGLABBEKE M
Citation: Mj. Piccart et al., CORTICOSTEROIDS SIGNIFICANTLY DELAY THE ONSET OF DOCETAXEL-INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED STUDY OF THE -ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER, Journal of clinical oncology, 15(9), 1997, pp. 3149-3155
RANDOMIZED TRIAL OF 2 REGIMENS OF CHEMOTHERAPY IN OPERABLE OSTEOSARCOMA - A STUDY OF THE EUROPEAN OSTEOSARCOMA INTERGROUP
Authors: SOUHAMI RL CRAFT AW VANDEREIJKEN JW NOOIJ M SPOONER D BRAMWELL VHC WIERZBICKI R MALCOLM AJ KIRKPATRICK A USCINSKA BM VANGLABBEKE M MACHIN D
Citation: Rl. Souhami et al., RANDOMIZED TRIAL OF 2 REGIMENS OF CHEMOTHERAPY IN OPERABLE OSTEOSARCOMA - A STUDY OF THE EUROPEAN OSTEOSARCOMA INTERGROUP, Lancet, 350(9082), 1997, pp. 911-917
STEROIDS DO REDUCE THE SEVERITY AND DELAY THE ONSET OF DOCETAXEL (DCT) INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED TRIAL OF THEEORTC INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER (IDBBC)
Authors: PICCART MJ KLIJN J PARIDAENS R NOOIJ M MAURIAC L COLEMAN R AWADA A SELLESLAGS J VANVRECKEM A VANGLABBEKE M
Citation: Mj. Piccart et al., STEROIDS DO REDUCE THE SEVERITY AND DELAY THE ONSET OF DOCETAXEL (DCT) INDUCED FLUID RETENTION - FINAL RESULTS OF A RANDOMIZED TRIAL OF THEEORTC INVESTIGATIONAL DRUG BRANCH FOR BREAST-CANCER (IDBBC), European journal of cancer, 31A, 1995, pp. 347-347
PHASE-II TRIAL FOR INTRAPERITONEAL CISPLATIN PLUS INTRAVENOUS-SODIUM THIOSULFATE IN ADVANCED OVARIAN-CARCINOMA PATIENTS WITH MINIMAL RESIDUAL DISEASE AFTER CISPLATIN-BASED CHEMOTHERAPY - A PHASE-II STUDY OF THE EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP
Authors: GUASTALLA JP VERMORKEN JB WILS JA GEORGE M SCOTTO V NOOIJ M HUINNINK WWT DALESIO O RENARD J
Citation: Jp. Guastalla et al., PHASE-II TRIAL FOR INTRAPERITONEAL CISPLATIN PLUS INTRAVENOUS-SODIUM THIOSULFATE IN ADVANCED OVARIAN-CARCINOMA PATIENTS WITH MINIMAL RESIDUAL DISEASE AFTER CISPLATIN-BASED CHEMOTHERAPY - A PHASE-II STUDY OF THE EORTC GYNECOLOGICAL CANCER COOPERATIVE GROUP, European journal of cancer, 30A(1), 1994, pp. 45-49
Risultati: 1-7 |